Journal
VIRUS RESEARCH
Volume 291, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.virusres.2020.198202
Keywords
Inhaled nitric oxide; COVID-19; SARS-CoV; Nanoparticles; Antiviral
Categories
Funding
- FAPESP [2018/08194-2, 2018/028327, DI20-1003]
- CNPq [404815/2018-9, 313117/2019-5]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) [001]
- REDES Project [180003]
Ask authors/readers for more resources
Nitric oxide plays a key role in the immune system and has shown potential in treating human coronavirus infections, including COVID-19. Through inhalation and the use of NO donors combined with nanomaterials, sustained release of NO can be achieved, enhancing its benefits and minimizing side effects.
The endogenous free radical nitric oxide (NO) plays a pivotal role in the immunological system. NO has already been reported as a potential candidate for use in the treatment of human coronavirus infections, including COVID-19. In fact, inhaled NO has been used in clinical settings for its antiviral respiratory action, and in the regulation of blood pressure to avoid clot formation. In this mini-review, we discuss recent progress concerning the antivirus activity of NO in clinical, pre-clinical and research settings, and its beneficial effects in the treatment of clinical complications in patients infected with coronaviruses and other respiratory viral diseases, including COVID-19. We also highlight promising therapeutic effects of NO donors allied to nanomaterials to combat COVID-19 and other human coronavirus infections. Nanomaterials can be designed to deliver sustained, localized NO release directly at the desired application site, enhancing the beneficial effects of NO and minimizing the side effects. Challenges and perspectives are presented to open new fields of research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available